PriceTargets.com logo

Pardes Biosciences - PRDS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.50
  • Forecasted Upside: 87.17%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.87 As of 06/2/2023 11:58 AM ET
+0 (0.00%)

This chart shows the closing price for PRDS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pardes Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRDS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRDS

Analyst Price Target is $3.50
▲ +87.17% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Pardes Biosciences in the last 3 months. The average price target is $3.50, with a high forecast of $5.00 and a low forecast of $2.00. The average price target represents a 87.17% upside from the last price of $1.87.

This chart shows the closing price for PRDS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in Pardes Biosciences. This rating has held steady since April 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2023SVB LeerinkDowngradeOutperform ➝ Market Perform$9.00 ➝ $2.00Low
4/4/2023SVB SecuritiesDowngradeOutperform ➝ Market PerformLow
4/3/2023Jefferies Financial GroupDowngradeBuy ➝ HoldLow
3/15/2023JMP SecuritiesLower TargetMarket Outperform$9.00 ➝ $5.00Low
1/27/2023SVB LeerinkLower TargetOutperform$12.00 ➝ $9.00Low
12/13/2022JMP SecuritiesInitiated CoverageMarket Outperform$9.00Low
8/16/2022SVB LeerinkLower TargetOutperform$18.00 ➝ $12.00Low
3/15/2022SVB LeerinkInitiated CoverageOutperform$18.00Low
1/18/2022Jefferies Financial GroupInitiated CoverageBuy$25.00Low
(Data available from 6/2/2018 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 0 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
5/3/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Pardes Biosciences logo
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $1.87
Low: $1.86
High: $1.88

50 Day Range

MA: $1.74
Low: $1.21
High: $1.95

52 Week Range

Now: $1.87
Low: $0.75
High: $6.04

Volume

9,967 shs

Average Volume

240,962 shs

Market Capitalization

$115.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Pardes Biosciences?

The following Wall Street sell-side analysts have issued research reports on Pardes Biosciences in the last twelve months: Jefferies Financial Group Inc., JMP Securities, SVB Leerink LLC, and SVB Securities.
View the latest analyst ratings for PRDS.

What is the current price target for Pardes Biosciences?

2 Wall Street analysts have set twelve-month price targets for Pardes Biosciences in the last year. Their average twelve-month price target is $3.50, suggesting a possible upside of 87.2%. JMP Securities has the highest price target set, predicting PRDS will reach $5.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $2.00 for Pardes Biosciences in the next year.
View the latest price targets for PRDS.

What is the current consensus analyst rating for Pardes Biosciences?

Pardes Biosciences currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PRDS, but not buy more shares or sell existing shares.
View the latest ratings for PRDS.

What other companies compete with Pardes Biosciences?

Other companies that are similar to Pardes Biosciences include Atossa Therapeutics, Capricor Therapeutics, Gossamer Bio, Nektar Therapeutics and Seelos Therapeutics. Learn More about companies similar to Pardes Biosciences.

How do I contact Pardes Biosciences' investor relations team?

Pardes Biosciences' physical mailing address is 900 LARKSPUR LANDING CIRCLE SUITE 150, SAN FRANCISCO CA, 94939. The company's listed phone number is 415-649-8758. The official website for Pardes Biosciences is www.pardesbio.com. Learn More about contacing Pardes Biosciences investor relations.